News
Sanofi successfully prices €1.5 billion bond issue Paris, June 17, 2025 - Sanofi announces that it has successfully priced its offering of €1.5 billion of notes across 2 tranches: €750 million ...
Paris, June 17, 2025 - Sanofi announces that it has successfully priced its offering of €1.5 billion of notes across 2 tranches: €750 million fixed-rate notes, due June 2029, bearing interest at an ...
Ventyx Biosciences has shared phase 2a data on a Parkinson’s disease prospect that has caught the eye of Sanofi. The readout shows the effect of VTX3232 on biomarkers, providing some of the data that ...
French pharmaceutical giant Sanofi announced on Tuesday that Tzield, the world's first and only therapy approved by the ...
Nielsen, who was diagnosed with MS aged 17, addressed NHS healthcare professionals, local government members and those in the ...
On June 9, Regeneron Pharmaceuticals and Sanofi (NASDAQ:SNY) announced promising interim results from the open-label Phase 4 ...
Explore more
Sanofi (NASDAQ: SNY) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds. Berenberg Bank analyst Luisa Hector ...
1h
Zacks Investment Research on MSNVerve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From LillyVerve Therapeutics VERV signed a definitive agreement with pharma bigwig Eli Lilly LLY. Per the terms, the pharma giant will ...
22h
Medpage Today on MSNBTK Inhibitors for Multiple SclerosisMultiple sclerosis (MS) includes both peripheral and central nervous system (CNS) inflammation, and an anti-inflammatory ...
GEN ranks not only the top 10 publicly traded developed of editing-based therapies, but the top five privately held companies ...
Looking at licensing deals struck in the past 10 years, Jefferies found that many Big Pharmas do not ultimately follow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results